Immunoglobulin a (IgA) Nephropathy Therapeutics Market Global Report 2026

The immunoglobulin A (IGA) nephropathy therapeutics market size has grown rapidly in recent years. It will grow from $1.09 billion in 2025 to $1.21 billion in 2026 at a compound annual growth rate (CAGR) of 11.7%. The growth in the historic period can be attributed to rising prevalence of chronic kidney disease, increasing awareness and diagnosis of IgA nephropathy, broader use of corticosteroid and immunosuppressive therapies, improvements in renal biopsy and diagnostic capabilities, and higher healthcare spending on nephrology care.

The immunoglobulin A (IGA) nephropathy therapeutics market size is expected to see rapid growth in the next few years. It will grow to $1.91 billion in 2030 at a compound annual growth rate (CAGR) of 12%. The growth in the forecast period can be attributed to advancements in precision medicine and biomarker-driven nephrology treatments, increasing adoption of biologic therapies and complement inhibitors, rising clinical research activity in IgA nephropathy treatments, expansion of early kidney disease screening programs, and growing investment in renal therapeutic development pipelines. Key trends include targeted complement inhibition approaches for slowing IgA nephropathy progression, development of monoclonal antibody therapies for immune-mediated kidney inflammation control, biomarker-based precision diagnostic and stratification methods, novel oral small-molecule therapies for reducing proteinuria and protecting renal function, and advanced drug delivery systems for sustained kidney-targeted therapeutic effects.

The rising incidence of chronic kidney disease (CKD) is expected to drive the growth of the immunoglobulin A (IgA) nephropathy therapeutics market going forward. Chronic kidney disease is a progressive disorder in which the kidneys are damaged over time and gradually lose their ability to filter blood effectively. The prevalence of chronic kidney disease is increasing due to a growing aging population, as kidney function naturally declines with age and older adults are more prone to diabetes and hypertension, which are major causes of kidney damage. Immunoglobulin A (IgA) nephropathy therapeutics support the management of chronic kidney disease (CKD) by targeting immune-mediated glomerular inflammation and proteinuria in IgA nephropathy, thereby slowing disease progression, preserving long-term kidney function, and reducing the likelihood of progression to end-stage renal disease. For instance, in June 2023, according to Kidney Research UK, a UK-based charitable organization, an estimated 7.19 million people in the UK were affected by chronic kidney disease in 2023, representing more than 10% of the UK population and expected to rise to 7.61 million people by 2033. Therefore, the rising incidence of chronic kidney disease (CKD) is driving the growth of the immunoglobulin A (IgA) nephropathy therapeutics market.

Leading companies operating in the immunoglobulin A (IgA) nephropathy therapeutics market are focusing on developing innovative targeted biologic therapies, such as anti-april monoclonal antibodies to reduce abnormal IgA production, slow disease progression, and preserve kidney function in patients with primary IgA nephropathy. Anti-april monoclonal antibodies are targeted biologic drugs that block APRIL (a protein involved in immune signaling) to reduce abnormal IgA antibody production, helping to lower kidney inflammation, reduce protein buildup in urine, and slow disease progression in IgA nephropathy. For example, in November 2025, Otsuka Pharmaceutical Co. Ltd., a Japan-based healthcare company, received U.S. Food and Drug Administration accelerated approval for Voyxact (sibeprenlimab-szsi), a novel anti-APRIL monoclonal antibody therapy for primary immunoglobulin A nephropathy. The treatment is designed to inhibit APRIL-mediated signaling pathways, thereby reducing pathogenic IgA production and immune complex deposition in the kidneys. It is administered as a biologic therapy aimed at slowing kidney function decline and reducing proteinuria in adults with IgA nephropathy at risk of disease progression, representing a significant advancement in targeted renal disease management.

In January 2024, Novartis AG, a Switzerland-based pharmaceutical company, acquired SanReno Therapeutics Co. Ltd. for an undisclosed consideration. With this transaction, Novartis AG seeks to reinforce its late-stage nephrology pipeline by obtaining rights to advanced therapies targeting Immunoglobulin A Nephropathy (IgAN), thereby accelerating the advancement and commercialization of innovative treatments for rare and progressive kidney disorders. SanReno Therapeutics Co. Ltd. is a China-based clinical-stage biopharmaceutical firm engaged in developing therapies for immunoglobulin A (IgA) nephropathy.

Major companies operating in the immunoglobulin A (IGA) nephropathy therapeutics market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Sanofi S.A., AstraZeneca PLC, Novartis AG, Bristol-Myers Squibb Company, Vertex Pharmaceuticals Incorporated, Otsuka Holdings Co. Ltd., Jiangsu Hengrui Pharmaceuticals Co. Ltd., Boehringer Ingelheim, Biogen Inc., Alnylam Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., Travere Therapeutics Inc., RemeGen Co. Ltd., Arrowhead Pharmaceuticals Inc., Apellis Pharmaceuticals Inc., BioCryst Pharmaceuticals Inc., Vera Therapeutics Inc., Transcenta Holding Limited, Shanghai Alebund Pharmaceuticals Co. Ltd., Kira Pharmaceuticals Inc., Purespring Therapeutics Ltd.

North America was the dominant region in the immunoglobulin A (IgA) nephropathy therapeutics market in 2025. Asia-Pacific is expected to be the rapidly expanding region in the forecast period. The regions covered in immunoglobulin A (IGA) nephropathy therapeutics report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the immunoglobulin A (IGA) nephropathy therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The immunoglobulin A (IgA) nephropathy therapeutics market consists of sales of oral therapeutic drugs, injectable therapies, targeted-release formulations, antibody-based therapies, complement pathway inhibitors, anti-inflammatory agents, and kidney disease management drugs. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

The immunoglobulin A (IGA) nephropathy therapeutics market research report is one of a series of new reports that provides immunoglobulin A (IGA) nephropathy therapeutics market statistics, including immunoglobulin A (IGA) nephropathy therapeutics industry global market size, regional shares, competitors with a immunoglobulin A (IGA) nephropathy therapeutics market share, detailed immunoglobulin A (IGA) nephropathy therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the immunoglobulin A (IGA) nephropathy therapeutics industry. This immunoglobulin A (IGA) nephropathy therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

This product will be delivered within 1-3 business days.